 DALLAS, Jan. 4, 2022 PRNewswire -- Lantern Pharma NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will be presenting at the H.C. 